<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02420730</url>
  </required_header>
  <id_info>
    <org_study_id>232411-001</org_study_id>
    <nct_id>NCT02420730</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety, tolerability, and systemic pharmacokinetics of up to 3
      different concentrations of AGN-232411 topical ophthalmic solution in healthy participants
      and participants with dry eye.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 56 days</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Cohort 1A: AGN-232411 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1B: AGN-232411 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose A in Cohort 1A is acceptable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1C: AGN-232411 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose B in Cohort 1B is acceptable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: AGN-232411 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop of Vehicle for AGN-232411 topical ophthalmic solution administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2A: AGN-232411 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2B: AGN-232411 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose A in Cohort 2A is acceptable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2C: AGN-232411 Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose B in Cohort 2B is acceptable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: AGN-232411 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop of Vehicle for AGN-232411 topical ophthalmic solution administered to the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-232411</intervention_name>
    <description>AGN-232411 topical ophthalmic solution</description>
    <arm_group_label>Cohort 1A: AGN-232411 Dose A</arm_group_label>
    <arm_group_label>Cohort 1B: AGN-232411 Dose B</arm_group_label>
    <arm_group_label>Cohort 1C: AGN-232411 Dose C</arm_group_label>
    <arm_group_label>Cohort 2A: AGN-232411 Dose A</arm_group_label>
    <arm_group_label>Cohort 2B: AGN-232411 Dose B</arm_group_label>
    <arm_group_label>Cohort 2C: AGN-232411 Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-232411 Vehicle</intervention_name>
    <description>Vehicle for AGN-232411 topical ophthalmic solution.</description>
    <arm_group_label>Cohort 1: AGN-232411 Vehicle</arm_group_label>
    <arm_group_label>Cohort 2: AGN-232411 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Stage 1

        -Healthy participants.

        Stage 2 -Participants with the symptoms of dry eye disease.

        Exclusion criteria:

        Stage 1

        -Known allergies or sensitivities to study medications, fluorescein, or lissamine green

        Stage 2

          -  Known allergies or sensitivities to study medications, fluorescein, or lissamine green

          -  Allergic ocular disease, ocular trauma, corneal erosions or ulcers, or uveitis within
             the previous 12 months

          -  History of any ocular surgery within the previous 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sall Research Center</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lugene Eye Institute</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montebello Medical Center, Inc.</name>
      <address>
        <city>Montebello</city>
        <state>California</state>
        <zip>90640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

